PAVmed Inc. (PAVM)
NASDAQ: PAVM · Real-Time Price · USD
0.7500
-0.0180 (-2.34%)
At close: Mar 28, 2025, 4:00 PM
0.7203
-0.0297 (-3.96%)
After-hours: Mar 28, 2025, 5:27 PM EDT
PAVmed Employees
PAVmed had 107 employees as of December 31, 2023. The number of employees decreased by 17 or -13.71% compared to the previous year.
Employees
107
Change (1Y)
-17
Growth (1Y)
-13.71%
Revenue / Employee
$27,991
Profits / Employee
$298,748
Market Cap
12.59M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
PAVM News
- 3 days ago - Lucid Diagnostics Launches "Embrace the Future" Campaign Showcasing EsoCheck's Groundbreaking Collect+Protect Esophageal Cell Collection Technology - PRNewsWire
- 5 days ago - PAVmed Inc. (PAVM) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 days ago - PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 6 days ago - Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 10 days ago - Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening - PRNewsWire
- 12 days ago - Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication - PRNewsWire
- 17 days ago - Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test - PRNewsWire
- 20 days ago - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025 - PRNewsWire